Industry top-down
Drug Manufacturers - General
Latest reported revenue & EPS across the covered companies in this industry, with year-over-year (YoY) change. From disclosed earnings — not investment advice.
AI industry top-down
Overall, sales growth trends across the pharmaceutical industry were mixed. While some companies recorded robust sales growth, many faced sales declines or stagnation. EPS, a key profitability metric, also showed varying trends across companies. Some companies saw EPS decline despite increased sales, while others managed to grow EPS even with a slight decrease in sales. This suggests significant disparities in company performance within the industry.
- Mixed revenue growth across companies
- Divergent trends in profitability metrics (EPS)
AI synthesis of disclosed results and analyst research across these companies — not investment advice.
Companies — latest quarter
| Company | Period | Revenue | Rev YoY | EPS | EPS YoY | Surprise |
|---|---|---|---|---|---|---|
| LLYELI LILLY & Co | FY2026 Q2 | $22.97B | +47.7% | $7.94 | +26.2% | — |
| JNJJOHNSON & JOHNSON | FY2026 Q2 | $25.31B | +6.6% | $2.27 | -0.9% | — |
| ABBVAbbVie Inc. | FY2026 Q2 | $16.99B | +10.2% | $2.03 | +290.4% | — |
| MRKMerck & Co., Inc. | FY2026 Q2 | $16.61B | +5.1% | $-0.54 | — | — |
| AMGNAMGEN INC | FY2026 Q2 | $10.05B | +9.5% | $4.37 | +64.9% | — |
| GILDGILEAD SCIENCES, INC. | FY2026 Q2 | $7.8B | +10.2% | $-8.45 | — | — |
| PFEPFIZER INC | FY2026 Q2 | $15.03B | +2.6% | $-0.04 | — | — |
| BMYBRISTOL MYERS SQUIBB CO | FY2026 Q2 | $12.97B | +5.7% | $1.62 | +153.1% | — |
| BIIBBIOGEN INC. | FY2026 Q1 | $2.48B | +1.9% | $2.15 | +31.1% | — |
| OGNOrganon & Co. | FY2026 Q2 | $1.56B | -2.3% | $0.40 | -28.6% | — |
| 317450MYUNGIN PHARM.CO., LTD | FY2026 Q2 | ₩76.11B | — | ₩1666.00 | — | — |
| AMRNAMARIN CORP PLCUK | FY2026 Q2 | $42.21M | -42.0% | $-0.02 | — | — |
| 307750KUKJEON Co.,Ltd | FY2026 Q2 | ₩40.48B | +21.4% | ₩19.00 | — | — |
| 004720PharmGen Science, Inc. | FY2026 Q2 | ₩47.72B | +4.0% | ₩-614.00 | — | — |
| SCLXScilex Holding Co | FY2026 Q2 | $7.64M | -22.8% | $-16.65 | — | — |
YoY = vs. the same quarter last year · Surprise = EPS actual vs. consensus. Latest reported quarter per company, from disclosed earnings filings. QoQ is omitted because quarterly filings don’t break out Q4 (US) and report cumulatively (KR).